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Aims Data mining is the computational process to obtain information from a data set and transform it for further use. Herein,
through data mining with supportive statistical analyses, we identified and consolidated variables of the Flecainide Short-
Long (Flec-SL—AFNET 3) trial dataset that are associated with the primary outcome of the trial, recurrence of per-
sistent atrial fibrillation (AF) or death.
Methods
and results
The ‘Ranking Instances by Maximizing the Area under the ROC Curve’ (RIMARC) algorithm was applied to build a clas-
sifier that can predict the primary outcome by using variables in the Flec-SL dataset. The primary outcome was time to
persistent AF or death. The RIMARC algorithm calculated the predictive weights of each variable in the Flec-SL dataset
for the primary outcome. Among the initial 21 parameters, 6 variables were identified by the RIMARC algorithm. In
univariate Cox regression analysis of these variables, increased heart rate during AF and successful pharmacological
conversion (PC) to sinus rhythm (SR) were found to be significant predictors. Multivariate Cox regression analysis re-
vealed successful PC as the single relevant predictor of SR maintenance. The primary outcome risk was 3.14 times (95%
CI:1.7–5.81) lower in those who had successful PC to SR than those who needed electrical cardioversion.
Conclusions Pharmacological conversion of persistent AF with flecainide without the need for electrical cardioversion is a powerful
and independent predictor of maintenance of SR. A strategy of flecainide pretreatment for 48 h prior to planned elec-
trical cardioversion may be a useful planning of a strategy of long-term rhythm control.
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Introduction
Cardioversion of persistent and long-standing persistent atrial fibril-
lation (AF) is a common intervention in patients who are in need for
rhythm control therapy. While this procedure restores sinus
rhythm (SR) very effectively in the acute setting,1 long-term
recurrences of AF are common after cardioversion.2,3 Identifying pa-
tients who are more likely to maintain SR for a longer time would
help develop a personalized planning of rhythm control therapy.
Unfortunately, such parameters are not well described.4
Data mining is the computational process of discovering patterns
in large datasets involving methods at the intersection of artificial
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intelligence, machine learning, statistics, and database systems. The
overall goal of the data mining process is to extract information
from a data set and transform it into an understandable structure
for further use.5 –7 Aside from the raw analysis step, it involves data-
base and data management aspects, data pre-processing, model and
inference considerations, interestingness metrics, complexity con-
siderations, post-processing of discovered structures, visualization,
and online updating.5 –7
The Flecainide Short-Long (Flec-SL—AFNET 3) trial2,8 is a pro-
spective, randomised, open-label, blinded endpoint assessment trial
that evaluated whether short-term antiarrhythmic drug treatment
was non-inferior to standard long-term treatment to prevent recur-
rent AF in patients undergoing elective cardioversion. This trial re-
vealed that short-term antiarrhythmic drug treatment after
cardioversion was non-inferior to long-term treatment in a cohort
of patients in whom electrical remodelling was thought to play a
large part in recurrent AF.2 Additionally, the study confirmed that
flecainide was effective in the prevention of recurrent AF after
cardioversion.
Here, we applied machine learning to determine predictors of
long-term maintenance of SR in the Flec-SL—AFNET-3 data set.
We used the RIMARC (Ranking Instances by Maximizing the Area
under the ROC Curve) classification algorithm.5,6 This algorithm
operates by ranking instances based on how likely they are to
have a positive label indicating the presence of a condition.7 By
means of this type of data mining analysis, we tried to extract clinic-
ally relevant statistical information from the Flec-SL—AFNET 3
database and seek for factors that might affect recurrence of persist-
ent AF after cardioversion, the primary outcome of the trial. We
then applied validation by biostatistical analysis.
Methods
Study design and participants
Between May 2007 and March 2010, 635 patients scheduled for planned
electrical cardioversion were enrolled into a prospective, randomized,
open-label, blinded endpoint assessment trial.8 Details of the trial design
and the primary outcome have been reported previously.2 Eligible
patients were adults with persistent AF undergoing planned cardiover-
sion. All patients received 48 h or more of treatment with the study drug
flecainide before planned electrical cardioversion. This was a mandatory
part of the protocol meant to ensure effective flecainide plasma levels at
the time of cardioversion. After successful cardioversion, patients were
randomly assigned in permuted blocks of six per center to: no antiar-
rhythmic drug treatment (control), treatment with flecainide for
4 weeks (short-term treatment) or flecainide for 6 months (long-term
treatment). The primary outcome was time to persistent AF or death.2
Data mining with RIMARC algorithm
The major aim of pursuing a data mining experiment on the Flec-SL da-
taset was to extract clinically relevant information. As in almost all wide-
ly used data mining techniques, the main objective was to reveal
underlying patterns in a data set and generate hypotheses over them, ra-
ther than describing the nature of the data and demonstrate the signifi-
cance of a model that relates the data instances to the underlying
population as conventional statistical methods mostly do. Data Mining
employs such techniques as linear and non-linear classification, cluster-
ing and association algorithms to identify trends to be fed into further
analyses.5–7 With this goal of using data mining for hypothesis and mod-
el generation, a supervised model based on the RIMARC (Ranking In-
stances by Maximizing the Area Under a (ROC) Curve) classification
algorithm5 was constructed. In this scope, RIMARC algorithm was
used to assign ‘predictive weights’, w e [0, 1], to each of the baseline clin-
ical parameter in the Flec-SL data set for addressing the ‘class label’ de-
noting whether a patient reaches the primary outcome or not.
Briefly, the RIMARC algorithm has been proven5 to constitute a rank-
ing function that attains the maximal area under the ROC curve (AUC)
for a given set of input parameters. The classification model learned by
the RIMARC algorithm can be used to estimate the likelihood, score(q),











wf qf is known
0 qf is missing
{
.
where wf represents the weight of the clinical parameter (feature) f, qf is
the value of the parameter (feature) f for patient q, and sf(q) is the score
associated with the value of the feature f for patient q.5,6 RIMARC algorithm
had been implemented as a proprietary suite in Java programming language
and the source codes with executables are available upon request.
Statistical analysis
We used the RIMARC algorithm to individually identify the predictive
power of parameters in predicting the primary outcome of the trial.
For this analysis, we have only included the parameters that were col-
lected at baseline and are biologically homogeneous. Full list can be
seen in Table 1. As the univariate classifier for each parameter is built
by RIMARC, the prediction accuracy of the calculated predictive weights
(w) are assessed in terms of AUC and their significances are validated by
the widely used 10-fold cross-validation technique. In 10-fold cross-
validation, the original sample is randomly partitioned into 10 equal
size subsamples. Of the 10 subsamples, a single subsample is retained
as the validation data for testing the model, and the remaining 9 subsam-
ples are used as training data. The cross-validation process is then re-
peated 10 times (number of folds), with each of the 10 subsamples
used exactly once as the validation data. The resulting risk classification
was later used to calculate the AUC and the 95% CI corresponding to
this AUC value.
What’s new?
† Data mining is a novel computational process to obtain infor-
mation from a data set and transform it for further use.
† In current study, through data mining with supportive statis-
tical analyses, we identified and consolidated variables of the
Flecainide Short-Long trial dataset that are associated with
the primary outcome of the trial, recurrence of persistent at-
rial fibrillation or death.
† Pharmacological conversion of persistent AF with flecainide
without the need for electrical cardioversion is a powerful
and independent predictor of maintenance of sinus rhythm.
† A strategy of flecainide pretreatment for 48 h prior to
planned electrical cardioversion may be a useful planning of
a strategy of long-term rhythm control.
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These intervals, here, provide the range in which the true AUC value
lies with CI 95%, indicating a significance level (a) of 0.05. To assess the
significance of AUC values found, one must point out the corresponding
confidence intervals that do not embrace the null hypothesis of AUC
being 0.500, that is the random classifier.9 If the null hypothesis is ‘em-
braced’ in any of the confidence intervals, then it is certainly not rejected
therein, the p-value must be greater than the significance level (a) of
0.05. On the other hand, if the 95% CI excludes the AUC value of
0.500, then the null hypothesis is said to be rejected, therefore, the
p-value must be less than the significance level (a) 0.05 which indicates
a statistical significance.5,6
This technique is useful when there is no separate test data set is avail-
able for validation, which is usually the case in the clinical domain. The
factors that were determined to have a statistically significant predictive
power via RIMARC were subject to univariate Cox regression analysis,
and were integrated into a multivariate Cox model using Stata data ana-
lysis software version 13.1.
Results
Variable selection and RIMARC-based
classifiers
By means of RIMARC algorithm, we obtained the predictive weights
(w) together with the AUC values of each baseline parameter asso-
ciated with recurrence of AF in other publications.4 After applying
10-fold cross-validation on the AUC values produced for each par-
ameter, mean AUC’s with 95% confidence intervals are calculated.
Among the initial 21 parameters, 6 variables were identified by the
RIMARC algorithm. These variables were heart rate, PC upon flecai-
nide pretreatment, body mass index, left ventricular ejection frac-
tion, baseline SF-12 physical, and mental component scores which
indicated as having significant AUC values in determining the pri-
mary outcome (Table 1).
Univariate and multivariate analysis
The 6 parameters at baseline determined also to have a statistically
significant discrimination power via RIMARC were subject to uni-
variate Cox regression analysis and were then used to build a multi-
variate Cox model. Increased heart rate during AF and PC upon
flecainide pretreatment were found to be the significant predictors
(significance level, a ¼ 0.05) in univariate Cox regression analysis.
The results of these analyses are presented in Table 2.
It can be seen that the parameter of pharmacological conversion
(PC) upon flecainide pretreatment is the single most relevant pre-
dictor of SR maintenance in multivariate Cox regression analysis.
The results of these analyses are presented in Table 3. Multivariate
Cox regression indicates that successful PC reduced the primary
outcome risk by 3.14 times [95% CI: 1.7–5.81] than those with
need for electrical cardioversion (hazard ratio: 0.318 [95% CI:
0.172–0.588]; P , a ¼ 0.05).
As illustrated in Figure 1, the Flec-SL dataset also shows that while
51% of patients who need electrical cardioversion reach the primary
endpoint, this proportion is 23% in those patients who undergo suc-
cessful PC. Therefore, the dataset also indicates that patients who
undergo successful PC are 2.22 (P , a ¼ 0.05) times less likely to
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The Kaplan–Meier survival analysis of the time-to-primary end-
point also indicates that the mean time-to-primary endpoint of pa-
tients who had successful PC is significantly higher than those
patients who needed electrical cardioversion. Figure 2 illustrates
the survival curves of patients who had successful PC and those
who needed electrical cardioversion.
Discussion
Using a combination of explorative data mining analyses and con-
firmation by ‘conventional’ univariate and multivariate Cox hazard
proportional models, we identified PC of persistent AF during in-
hospital flecainide initiation as an important predictor of longer
term maintenance of SR after cardioversion of persistent AF. Pa-
tients who were cardioverted back to SR during oral pretreatment
with flecainide for 48 h prior to scheduled electrical cardioversion
were more than three times as likely to maintain SR for 6 months
after cardioversion. Other clinical variables, including duration of
AF and atrial size, were not predictive of recurrent AF in this large
data set of patients with persistent and long-standing persistent AF.
Several mechanisms cause recurrent AF after cardioversion. In
addition to electrical remodelling, structural changes in the atria,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Univariate cox regression analysis
B SE Sig.
(a 5 0.05)
HR 95.0% CI for
HR







Heart rate 20.010 0.003 0.001 0.990 0.984 0.996 287 347 1
PC upon flecainide pretreatment 21.033 0.196 0.000 0.356 0.242 0.523 287 348 0
BMI 0.000 0.012 0.993 1.000 0.976 1.025 284 343 0
Left ventricular ejection fraction 0.009 0.008 0.248 1.009 0.994 1.024 233 301 101
SF-12, physical component,
baseline
20.011 0.007 0.095 0.989 0.976 1.002 206 216 213
SF-12, mental component,
baseline
0.005 0.007 0.499 1.005 0.991 1.018 205 220 210
BMI, body mass index; PC, pharmacological cardioversion.
. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Multivariate cox regression analysis (full model)
B SE Sig.
(a 5 0.05)
HR 95.0% CI for HR
Lower Upper
Heart rate 20.005 0.004 0.269 0.995 0.987 1.004
PC upon flecainide pretreatment 21.080 0.278 0.000 0.340 0.197 0.586
BMI 20.003 0.016 0.864 0.997 0.966 1.029
Left ventricular ejection fraction 0.013 0.009 0.171 1.013 0.995 1.031
SF-12, physical component, baseline 20.010 0.008 0.178 0.990 0.975 1.005
SF-12, mental component, baseline 0.001 0.008 0.925 1.001 0.986 1.016
N %





Cases with missing values 265 41.7
Cases with negative time 0 0.0
Censored cases before the earliest event in a stratum 0 0.0
Total 265 41.7
Total 635 100.0
BMI, body mass index; PC, pharmacological cardioversion.
aDependent variable: time to event (days).
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focal firing from the pulmonary veins, and abnormal myocardial cal-
cium handling can cause recurrences.10,11 Antiarrhythmic drugs
such as flecainide prolong the action potential, increase post-
repolarization refractoriness, and increase the curvature of electric-
al wave fronts in the left atrium, thereby contributing to termination
of fibrillatory activity. In addition, flecainide can also prevent focal
firing and abnormal intracellular calcium handling.8,12
Pretreatment with flecainide prior to planned electrical cardio-
version of AF has not been systematically evaluated before. Al-
though therapeutic antiarrhythmic drug levels immediately after
cardioversion can prevent immediate recurrences of AF, pretreat-
ment does not routinely used in common clinical practice. None-
theless, some observational data sets are available for patients
pretreated with amiodarone13 and dofetilide14: Galperı́n et al.13 ana-
lysed the role of different parameters that determine long-term SR
maintenance in patients with persistent AF who are treated with
amiodarone. They enrolled 141 anticoagulated patients with persist-
ent AF who were pretreated for 4 weeks with oral amiodarone.
Those in whom the arrhythmia persisted underwent electric cardi-
oversion. After restoration of normal SR (either pharmacologic or
electric), all patients received a daily dose of amiodarone and
were followed 2 years. Concordant with our findings, PC during
pretreatment was one of the major determinants for long-term SR
maintenance.13
Malhotra et al.14 retrospectively reviewed elective inpatient ad-
missions for dofetilide loading. They used a multivariate Cox pro-
portional hazards model to assess predictors of maintenance of
SR after in-hospital dofetilide loading. They found that patients
who converted pharmacologically upon dofetilide pretreatment re-
mained longer in SR compared with the patients who required elec-
trical cardioversion.14 Thus, our main finding is in line with other
reports on other antiarrhythmic drugs.
0.0
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Figure 1 Distribution of patients who had recurrence of persist-
ent AF and who were in SR (i.e. do not reach the primary endpoint)
at the end of the 6-month follow-up period.
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Recent epicardial mapping data suggest that the electrical com-
plexity of AF differs markedly between patients with persistent
AF.15,16 Although we cannot provide definite proof for this hypoth-
esis, it is possible that PC of persistent AF during flecainide pretreat-
ment could be a marker for low complexity of AF.17,18 Furthermore,
it is conceivable that PC of AF identifies a group of patients who are
responsive to therapy with flecainide which was given to the major-
ity of patients during follow-up.2
The main reason why RIMARC was selected as the data mining
algorithm of choice is the proven accuracy and performance of
RIMARC algorithm, and that it yields easily interpretable and
clinically relevant results. The predictive performance of RIMARC
algorithm over a wide range of commonly used data mining algo-
rithms with 10 benchmark data sets was shown in comparative
experiments.5 The comparison is made on the AUC metric owing
to the fact that it is a widely accepted in evaluating the accuracy of
a classification performance. Valid arguments were theoretically and
empirically supplied as to why AUC should be preferred over accur-
acy, which is merely a ratio of correctly predicted results to the total
number of instances examined.19,20 A higher value of AUC for a par-
ameter is an indication of its higher relevance in determining the
class label. Since RIMARC algorithm aims to maximize the AUC
value directly, it outperforms the other data mining algorithms on
average, with a statistically significant difference.5 –7
Furthermore, RIMARC has several advantages compared with
other algorithms of medical data mining and decision support, which
can be summarized as follows:
(i) RIMARC is a non-parametric machine learning method, thus
no parameter tuning is needed to attain an optimal classifier.
(ii) RIMARC is highly robust to the frequently encountered ‘miss-
ing value’ problem in clinical datasets.
(iii) RIMARC’s main output is a human-readable, intuitive ‘ranking
function’ that lists the order of influence of input variables
and their impacts (i.e.’weights’) on the ranking function.
(iv) The impacts of individual input variables on the ranking func-
tion are calculated independently. Therefore, any addition or
removal of variables does not affect the individual weights of
the input variables in the classifier.5,6
Limitations
The present analysis is a retrospective analysis of the Flec-SL—AF-
NET 3 data set. The data set provides information on a large
contemporary cohort of patients undergoing cardioversion of AF.
In addition, the data mining used, where the hypothesis is not pre-
specified, and the study is initially hypothesis free. As any retrospect-
ive analysis, it is hypothesis generating. This is a large cohort of
patients, many of whom have long-standing AF (mean duration 28
months), therefore spontaneous conversions occurred in 20%
of patients.
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Sinkhole syncope
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A 53-year-old woman presented in complete heart block after an epi-
sode of syncope. She was hanging out washing when a 5 m deep sink-
hole opened up beneath her.
On arrival to our emergency department, the patient was lucid and
asymptomatic. The clinical examination was unremarkable.
Twelve-lead electrocardiogram showed sinus rhythm with third-
degree atrioventricular (AV) block and a junctional escape of
50 bpm (Panel A). Initial investigations were unremarkable.
Transthoracic echocardiogram demonstrated severely reduced left
ventricular (LV) ejection fraction with akinesis of all mid-myocardial
segments extending into adjacent basal and apical segments but spar-
ing true apex and the very base (Panel B).
Three hundred and twenty-slice computed tomography coronary
angiogram demonstrated no coronary atherosclerosis (Panel C), con-
firming the clinical suspicion that the patient’s abnormal LV contrac-
tion represented a stress cardiomyopathy.
The patient remained in complete heart block with a stable junc-
tional escape rhythm (40–50 bpm). Seven days post-admission, a re-
peat transthoracic echocardiogram demonstrated normalization of LV
contraction (Panel D), yet complete heart block persisted. A dual-
chamber permanent pacemaker was inserted.
There have been rare reports of high-degree AV block and
takotsubo cardiomyopathy occurring together in medical literature.
Occasionally, cardiomyopathy persists after improvement of left ven-
tricular wall motion necessitating implantation of a permanent
pacemaker.
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